Japan’s Nippon Chemiphar gets a grip on a decline in pharmaceutical sales seen earlier this year, on the back of strong sales of generic drugs launched last year. The company also expects an upward impact from expanded sales of generic drugs achieved through sales channel diversification efforts for its current financial year ending 31 March 2022. 

Strong sales of Dupixent and its range of vaccines are expected to drive Sanofi’s financial results for the first quarter of 2021, although these are likely to have been adversely affected by currency exchange rate movements. Numerous data readouts are expected in the coming months from pipeline products.

Norway’s Pre Diagnostics uses the intracellular approach to neurodegenerative disease diagnosis. It believes its technology will open up a world of precision medicine for Alzheimer’s disease patients.

In an interview, oncology development exec Peter Adamson reiterated the company’s view that THOR-707 is best-in-class, but more data are needed to see where its efficacy stands amid the IL-2 herd.